Cancer Letters
Volume 210, Issue 1 , Pages 101-109 , 8 July 2004

p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy

  • Reiping Tang

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
    • ,
  • Jeng-Yi Wang

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Jar-Yi, Taiwan, ROC
    • ,
  • Chung-Wei Fan

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
    • ,
  • Kuo-Chien Tsao

      Affiliations

    • Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
    • ,
  • Hong-Hua Chen

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC
    • ,
  • Chi-Ming Wu

      Affiliations

    • Graduate Institute of Basic Medical Science, Chang Gung University, Tao-Yuan, Taiwan, ROC
    • ,
  • Jinn-Shiun Chen

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
    • ,
  • Chung Rong Changchien

      Affiliations

    • Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
    • ,
  • Ling-Ling Hsieh

      Affiliations

    • Department of Public Health, Chang Gung University, 259 Wen-Hwa 1 Road, Kwei-San, Tao-Yuan 333, Taiwan, ROC
    • Corresponding Author InformationCorresponding author. Tel.: +886-3-211-8800x5125; fax: +886-3-211-8700

Received 8 August 2003 ,Revised 10 January 2004 ,Accepted 15 January 2004.

References 

  1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–627
  3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  4. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, et al. Convention on nomenclature for DNA cytometry, Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet. Cytogenet. 1984;13:181–183
  5. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial pre-disposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257
  6. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 1990;87:7555–7559
  7. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, et al.  Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993;53:5849–5852
  8. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al.  Tumor Microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000;342:69–77
  9. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J. Natl. Cancer Inst. 1999;91:1295–1303
  10. Update of recommendations for the use of tumor markers in breast and colorectal cancer, Adopted on November 7, 1997 by the American Society of Clinical Oncology . J. Clin. Oncol. 1998;16:793–795
  11. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al.  American Society of Clinical Oncology Tumor Markers Expert Panel, 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001;19:1865–1878
  12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–810
  13. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes’ C colon carcinoma. Oncology. 2000;58:52–59
  14. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 1995;122:321–326
  15. NIH consensus conference . adjuvant therapy for patients with colon and rectal cancer. J. Am. Med. Assoc. 1990;264:1444–1450
  16. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol. 1989;1:1447–1456
  17. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators: efficacy of adjuvant fluorouracil and folinic acid in colon cancer, Lancet, 345 (1995) pp.939–944.
  18. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 1999;17:1349–1355
  19. World Health Organization, International histological classification of tumours, Geneva, World Health Organization, 1969-1981, 2nd ed., Berlin, Springer-Verlag, 1988-Present.
  20. In:  Fleming ID,  Cooper JS,  Henson DE,  Hutter RVP,  Kennedy BJ,  Murphy GP, et al. editor. American Joint Committee on Cancer Staging Manual. 5th ed.. Philadelphia: JB Lippincott; 1997;
  21. Tang R, Wang PF, Wang HC, Wang JY, Hsieh LL. Mutations of p53 gene in human colorectal cancer: distinct frameshifts among populations. Int. J. Cancer. 2001;91:863–868
  22. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB. Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene. 1989;4:923–928
  23. Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int. J. Cancer. 1996;66:332–336
  24. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749–4756
  25. Tang R, Ho YS, You YT, Hsu KC, Chen JS, Changchien CR, et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer. 1995;76:1724–1730
  26. Slattery ML, Curtin K, Anderson K, Ma KN, Edwards S, Leppert M, et al.  Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res. 2000;60:6935–6941
  27. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al.  p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J. Clin. Oncol. 1999;17:1375–1381
  28. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al.  Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149–1158
  29. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 2001;19:299–304
  30. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al.  Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 1992;102:1136–1141
  31. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2001;344:1196–1206
  32. Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, et al. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J. Pathol. 1999;188:14–17
  33. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, et al.  Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis. Colon Rectum. 2001;44:358–363
  34. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis. Colon Rectum. 2001;44:322–333
  35. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 2001;7:1343–1349
  36. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 2003;21:241–250
  37. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer. 2002;99:597–602
  38. Taal BG, Van Tinteren H, Zoetmulder F, NACCP group . Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br. J. Cancer. 2001;85:1437–1443

PII: S0304-3835(04)00050-3

doi: 10.1016/j.canlet.2004.01.006

Cancer Letters
Volume 210, Issue 1 , Pages 101-109 , 8 July 2004

Article Tools

* Image Usage & Resolution